Hot flashes caused by cancer therapy can be prevented, treated

(Reuters Health) - Cancer patients with hot flashes related to hormone therapy should know that these uncomfortable symptoms can be managed, according to a recently published resource for patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Researchers from the University of Wisconsin School of Medicine and Public Health have discovered a new way to measure the efficacy or failure of hormone therapy for breast cancer patients. A study detailing the findings was published in the February issue of The Journal of Nuclear Medicine. The findings showed that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been found to successfully measure changes in progesterone receptor (PR) levels resulting from a short-course estrogen treatment, also known as an estradiol challenge. Estrogen-receptor (ER)-positive breast cancer is...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
(Society of Nuclear Medicine and Molecular Imaging) Physicians may soon have a new way to measure the efficacy of hormone therapy for breast cancer patients, according to research published in the February issue of The Journal of Nuclear Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health&Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future r...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
ConclusionsThe emergence of new drugs for mCRPC has improved treatment options dramatically. Currently, systemic treatment options for mCRPC include hormonal therapy, chemotherapy, immunotherapy, and radionuclide therapy as well as bone-modifying agents and palliative or supportive measures. Further, new genetically targeted agents (PARP inhibitors and PD-1 inhibitors) are on the horizon for certain subsets of biomarker-selected patients. The best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear.Patient summaryT...
Source: European Urology - Category: Urology & Nephrology Source Type: research
(American Association for Cancer Research) An evaluation of breast cancer patients enrolled in Medicaid showed that states that expanded Medicaid during 2011 to 2017 had a 27 percent increase in prescriptions for hormonal therapy medications compared to states that did not expand Medicaid during the same period.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: Our study suggests that inhibition of the IGF pathway may be an effective strategy for ER-positive breast cancer therapy, even in hormone therapy-resistant cases. PMID: 30328006 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
anMeter JW, Saykin AJ, Ahles T Abstract PURPOSE: To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS: Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuro...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
This research article found patients who received CM were more likely to refuse additional conventional cancer treatment (surgery/chemo or radio or hormone therapy) and had higher risk of death.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Authors: Abstract The diagnosis of cancer in females younger than 20 years is rare, with the incidence of 17 cases per 100,000 individuals per year in the United States. Although advancements in cancer therapy have dramatically improved childhood cancer survival, gynecologists should be aware of the increased risk of adverse reproductive health effects from each type of therapy. Cancer and its treatment may have immediate or delayed adverse effects on reproductive health. Gynecologists may be consulted for the following issues: pubertal concerns; menstrual irregularities; heavy menstrual bleeding and anemia; sexu...
Source: Obstetrics and Gynecology - Category: OBGYN Tags: Obstet Gynecol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hormonal Therapy | Hormones